The EHR4CR Project

The EHR4CR project runs over 5 years (2011-2015) with a budget of +16 million € and involves 34 partners (academic and industrial) and 2 subcontractors. It is being funded by Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) . EHR4CR is one of the largest public-private partnerships aiming at providing adaptable, reusable and scalable solutions (tools and services) for reusing data from Electronic Health Record systems for Clinical Research. Electronic Health Record (EHR) data offer large opportunities for the advancement of medical research, the improvement of healthcare, and the enhancement of patient safety.

Interviews: in following video, key partners explain their vision on the project.[01/04/2014]

Platform and Services

The EHR4CR platform is a service platform unlocking EHR data for research purposes that ensures compliance with data protection and patient rights legislation.

The EHR4CR services

  • Protocol Feasibility (distributed queries)
  • Patient Recruitment (distributing trial protocols to sites and collecting follow-up information on recruitment status from sites)
  • Clinical Trial Execution & Serious Adverse Events Reporting (mainly EHR extraction).

Pilots

  • For the different Scenarios
  • Across different Therapeutic Areas (oncology, inflammatory diseases, neuroscience, diabetes, cardiovascular diseases)
  • Across different Countries (under different legal frameworks).

Business Model

  • A self-sustaining Economic Model
  • Stakeholder Value Propositions
  • Standards and specifications
  • Accreditation and Certification plans
  • Governance of platform services and networks
  • The European Institute For Innovation Through Health Data and the first CoE on the reuse of health data
  • A Roadmap for pan-European adoption and for funding future developments.

Accreditation

Accreditation of Clinical Research Units and Certification of EHR systems will accelerate the adoption of a more harmonised approach throughout Europe and serve as a powerful means for ensuring to the pharmaceutical industry the reliability and trustworthiness of the data providers.